TERN — Terns Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Terns Pharmaceuticals Reports Topline 12-Week Data From Its Phase 2 Trial Evaluating Oral Glp-1 Receptor Agonist Tern-601 In Obesity
Terns Pharma ends obesity drug program after mid-stage trial data
Terns Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Terns Pharmaceuticals Q2 Net Income USD -24.093 Million Vs. IBES Estimate USD -26.6 Million
Terns Pharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration
U.S. STOCKS ON THE MOVE-Caterpillar, Starbucks, Lockheed Martin
U.S. STOCKS ON THE MOVE-Vaxart, DoubleVerify, Cracker Barrel
U.S. STOCKS ON THE MOVE-MP Materials, Ouster, Tesla
U.S. STOCKS ON THE MOVE-Quantum computing stocks, Grab Holdings, Talen Energy
Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says
Terns Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Terns Pharmaceuticals Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Terns Pharmaceuticals Files For Mixed Shelf Offering Of Up To $300 Million- SEC Filing
Brief: Terns Pharmaceuticals Reports Inducement Grant To New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp
Brief: Terns Pharmaceuticals Cash & Cash Equivalents Expected To Provide Runway Into 2028
Brief: Terns Pharmaceuticals Appoints Robert Azelby To Board Of Directors